Are we ready to stratify BI-RADS 4 lesions observed on magnetic resonance imaging? A real-world noninferiority/equivalence analysis

Author:

Almeida João Ricardo Maltez de1ORCID,Bitencourt Almir Galvão Vieira2ORCID,Gomes André Boechat1ORCID,Chagas Gabriela Lemos1ORCID,Barros Thomas Pitangueira1ORCID

Affiliation:

1. CAM – Clínica Médica e Imagem (Grupo Oncoclínicas), Brazil

2. A.C.Camargo Cancer Center, Brazil

Abstract

Abstract Objective: To demonstrate that positive predictive values (PPVs) for suspicious (category 4) magnetic resonance imaging (MRI) findings that have been stratified are equivalent to those stipulated in the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) for mammography and ultrasound. Materials and Methods: This retrospective analysis of electronic medical records generated between January 4, 2016 and December 29, 2021 provided 365 patients in which 419 suspicious (BI-RADS category 4) findings were subcategorized as BI-RADS 4A, 4B or 4C. Malignant and nonmalignant outcomes were determined by pathologic analyses, follow-up, or both. For each subcategory, the level 2 PPV (PPV2) was calculated and tested for equivalence/noninferiority against the established benchmarks. Results: Of the 419 findings evaluated, 168 (40.1%) were categorized as malignant and 251 (59.9%) were categorized as nonmalignant. The PPV2 for subcategory 4A was 14.2% (95% CI: 9.3–20.4%), whereas it was 41.2% (95% CI: 32.8–49.9%) for subcategory 4B and 77.2% (95% CI: 68.4–84.5%) for subcategory 4C. Multivariate analysis showed a significantly different cancer yield for each subcategory (p < 0.001). Conclusion: We found that stratification of suspicious findings by MRI criteria is feasible, and malignancy probabilities for sub-categories 4B and 4C are equivalent to the values established for the other imaging methods in the BI-RADS. Nevertheless, low suspicion (4A) findings might show slightly higher malignancy rates.

Publisher

FapUNIFESP (SciELO)

Reference32 articles.

1. Cancer statistics, 2023;Siegel RL;CA Cancer J Clin,2023

2. Screening for breast cancer;Niell BL;Radiol Clin North Am,2017

3. Breast cancer;Harbeck N;Nat Rev Dis Primers,2019

4. Breast cancer screening in women at higher-than-average risk: updated recommendations from the ACR;Monticciolo DL;J Am Coll Radiol,2023

5. Breast MRI: guidelines from the European Society of Breast Imaging;Mann RM;Eur Radiol,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3